



Corrigendum

High Body Mass Index is Correlated with the Success of Vonoprazan-Based Second-Line Therapy for *Helicobacter Pylori* Infection

Toyotaka Kasai,^{1,2} Sho Suzuki,^{2,3} Chika Kusano,² Hisatomo Ikehara,²
Ryoji Ichijima,² Motoki Ohyauchi,⁴ Masashi Kawamura,⁵ Yoshioki Yoda,⁶
Moriyasu Nakahara,⁷ Koichi Kawabe¹ and Takuji Gotoda²

¹Department of Gastroenterology, Fukaya Red Cross Hospital, Fukaya, Saitama, Japan

²Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

³Department of Gastroenterology, Yuri Kumiai General Hospital, Yurihonjo, Akita, Japan

⁴Department of Gastroenterology, Osaki Citizen Hospital, Osaki, Miyagi, Japan

⁵Department of Gastroenterology, Sendai City Hospital, Sendai, Miyagi, Japan

⁶Yamanashi Koseiren Health Care Center, Kofu, Yamanashi, Japan

⁷Department of Gastroenterology, Chichibu Municipal Hospital, Chichibu, Saitama, Japan

Tohoku J. Exp. Med., 253: 85-94, 2021. doi: 10.1620/tjem.253.85.

In the version of this article published in the February issue, 2021, the author mistook the affiliation of the first author. The correct affiliation of Toyotaka Kasai is Department of Gastroenterology, Fukaya Red Cross Hospital, Fukaya, Saitama, Japan and Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.

Concerning the “Table 1” (Page 91) of this article, the authors found that the sex item was missing. Table 1 added sex item is the next page. The authors sincerely apologize for the oversight on this matter.

Received November 10, 2022; revised and accepted November 21, 2022; doi: 10.1620/tjem.2022.J099

Correspondence: Sho Suzuki, M.D., Ph.D., Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 1-6 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-8309, Japan.

e-mail: s.sho.salubriter.mail@gmail.com

©2023 Tohoku University Medical Press. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0). Anyone may download, reuse, copy, reprint, or distribute the article without modifications or adaptations for non-profit purposes if they cite the original authors and source properly.
<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Table 1. Relationship between patient factors and the success or failure of vonoprazan-based second-line therapy for Hp eradication.

	Eradication success group (n = 27)	Eradication failure group (n = 6)	P value
Age (years, mean ± SD)	63.0 ± 11.1	62.1 ± 9.4	
Range	34-79	49-73	
Age (≥ 58 years/< 58 years)	22/5	3/3	0.271
Sex (male/female)	18/9	4/2	1.000
Height (cm, mean ± SD)	163.6 ± 10.3	161.0 ± 10.7	
Range	142-188	151-180	
Height (≥ 157 cm/< 157 cm)	21/6	2/4	0.099
Body weight (kg, mean ± SD)	65.4 ± 12.4	58.9 ± 9.4	
Range	37.8-90.0	47.0-76.0	
Body weight (≥ 56 kg/< 56 kg)	21/6	2/4	0.099
Body mass index (kg/m ² , mean ± SD)	24.3 ± 3.2	22.6 ± 0.9	
Range	16.1-28.8	20.6-23.5	
Body mass index (≥ 23.8 kg/m ² / <lt; 23.8="" kg="" m<sup="">2)</lt;>	19/8	0/6	0.007
Cigarette smoking (+/-)	5/22	3/3	0.271
Alcohol consumption (+/-)	5/22	1/5	1.000
Daily PPI use before the trial (+/-)	1/26	0/6	1.000
MIC value for metronidazole (≥ 32 µg/mL/< 32 µg/mL)	4/23	0/6	0.753
MIC value for amoxicillin (≥ 0.03 µg/mL/< 0.03 µg/mL)	5/22	1/5	1.000
Presence of <i>Helicobacter pylori</i> -related disease			
Total (+/-)	8/19	0/6	0.315
Gastric ulcer (+/-)	2/25	0/6	1.000
Duodenal ulcer (+/-)	5/22	0/6	0.607
ER for gastric neoplasia (+/-)	1/26	0/6	1.000

The chi-square test was used for categorical variables. The presence of *Helicobacter pylori*-related diseases was defined as having a history of gastric ulcers, duodenal ulcers, or ER for gastric neoplasia. The success rate of vonoprazan-based second-line therapy was greater in the high-BMI patient group (≥ 23.8 kg/m²) than in the low-BMI patient group (< 23.8 kg/m²; $p = 0.007$). No correlations were observed between eradication success and other patient factors, including the metronidazole/amoxicillin MICs.

BMI, body mass index; ER, endoscopic resection; Hp, *Helicobacter pylori*; MIC, minimal inhibitory concentration; PPI, proton pump inhibitor; SD, standard deviation; vonoprazan-based second-line therapy, vonoprazan with amoxicillin and metronidazole therapy.